Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...

This expansion positions Dupixent as the first targeted therapy for COPD ... Further boosting the pipeline, mid-stage drugs ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Dupixent, being jointly developed by Sanofi and Regeneron under a global collaboration deal, is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways and is ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...